Visit https://www.peervoice.com/UCD860 to view the entire programme with slides. After completing “When Physics Fuses With Medicine: A New Therapeutic Modality for mCRPC”, participants will be able to: Define the clinical intent of a dual diagnostic/therapeutic radioligand strategy; Describe the rationale for targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) using a theranostic approach; Propose how the current clinical experience with emerging radioligand therapies for mCRPC informs future clinical practice.